Exact Sciences reported a 23% year‑over‑year revenue increase for Q4 2025 and beat consensus on screening volumes, lifting momentum ahead of a special shareholders’ meeting to approve Abbott’s proposed $23 billion acquisition. CEO Kevin Conroy framed the quarter as evidence of expanding core product demand, with screening revenue up materially and precision oncology testing also growing. The company remains unprofitable on a GAAP basis but reduced losses compared with the prior year. Investors will weigh the growth narrative against deal terms and regulatory scrutiny as the takeover vote approaches.